New Technical Report: Biolojic Design’s AI-Powered Platform Enables Systematic Engineering of Dual-Specific ‘Two-in-One’ IgG Antibodies (Multibodies) Against Any Target Pair

By webadmin@biolojic.com|2026-05-18T10:33:25+00:00May 18, 2026|News|Comments Off on New Technical Report: Biolojic Design’s AI-Powered Platform Enables Systematic Engineering of Dual-Specific ‘Two-in-One’ IgG Antibodies (Multibodies) Against Any Target Pair

Read More

Biolojic presented the first ever preclinical data on a multibody-drug conjugate, BD200, at the AACR 2026

By webadmin@biolojic.com|2026-05-04T07:19:12+00:00April 19, 2026|News|Comments Off on Biolojic presented the first ever preclinical data on a multibody-drug conjugate, BD200, at the AACR 2026

Read More

Biolojic Design Earns Preclinical Milestone from Teva for First AI-Designed Multibody in Autoimmune Disease, TEV ‘325 (formerly BD9)

By webadmin@biolojic.com|2026-03-25T16:04:41+00:00March 25, 2026|Press Release|Comments Off on Biolojic Design Earns Preclinical Milestone from Teva for First AI-Designed Multibody in Autoimmune Disease, TEV ‘325 (formerly BD9)

Read More

Biolojic Design Appoints Roger Waltzman as Chief Medical Officer

By webadmin@biolojic.com|2026-01-11T13:17:45+00:00January 11, 2026|News|Comments Off on Biolojic Design Appoints Roger Waltzman as Chief Medical Officer

Read More

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

By webadmin@biolojic.com|2025-05-28T09:12:17+00:00May 28, 2025|News|0 Comments

Read More

A novel therapeutically active anti-TNFR2 agonistic antibody promotes Treg proliferation and induction of Treg functional markers

By webadmin@biolojic.com|2024-08-06T09:42:32+00:00July 10, 2024|Publication|0 Comments

Read More

Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024

By webadmin@biolojic.com|2024-06-25T13:25:24+00:00June 12, 2024|News|0 Comments

Read More

Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany.

By webadmin@biolojic.com|2024-08-26T08:51:38+00:00June 3, 2024|News|0 Comments

Read More

A Novel Computationally Designed Multibody Targeting IL-13/TSLP for Precision Therapy in TH2-Mediated Diseases

By webadmin@biolojic.com|2024-08-06T09:35:51+00:00May 14, 2024|Publication|0 Comments

Read More

Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases

By webadmin@biolojic.com|2024-06-05T12:40:33+00:00April 24, 2024|News|0 Comments

Read More